Role of ¹⁸F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis

Abstract

The aim of this study was to collect the evidence on the performance of 2-deoxy-2-[18F]fluoro-D-glucose (¹⁸F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in terms of detection rate (DR) and diagnostic accuracy in identifying hematogenous metastases in patients with differentiated thyroid cancer and compare its performance with that of other imaging techniques. A comprehensive PubMed/MEDLINE database research was carried out to retrieve studies documenting the performance of ¹⁸F-FDG PET/CT in depicting hematogenous metastases in patients with differentiated thyroid cancer. Statistical analysis was performed on a per-patient and per-lesion basis. The literature search yielded 15 articles to be included in the systematic review. ¹⁸F-FDG PET/CT showed a pooled DR of 85.08% on a per-patient analysis and 89.70% on a per-lesion analysis. For bone lesions, a high DR (81.78%) was found for ¹⁸F-FDG PET/CT. For the sub-group analysis of lung lesions, pooled DR was 92.77% for ¹⁸F-FDG PET/CT, 95.02% for CT, and 64.93% for magnetic resonance imaging (MRI). On a per-patient analysis, ¹⁸F-FDG PET/CT demonstrated a pooled sensitivity (SS) of 87.3% [95% confidence interval (CI): 77.3%-94%] and a pooled specificity (SP) of 95.6% (95%CI: 87.6-99.1). On a per-lesion analysis (328 metastases), PET/CT showed a pooled SS and SP of 86.3% (95%CI: 73.5%-93.5%) and 93.4% (95%CI: 71.7%-98.8%) in the detection of hematogenous metastases. The presented systematic review and meta-analysis favor the use of ¹⁸F-FDG PET/CT in the detection of hematogenous metastases in patients with differentiated thyroid cancer. The limited literature warrants further studies to confirm our findings.

Keywords

PET/CT / hematogenous metastases / lung / bone / thyroid cancer / FDG / meta-analysis

References

[1] Asa SL.The current histologic classification of thyroid cancer..Endocrinol Metab Clin North Am2019;48:1-22

[2] Giovanella L.Thyroglobulin measurement in differentiated thyroid carcinoma management..Expert Rev Endocrinol Metab2008;3:117-25

[3] Raue F.Raue F.Long-Term Follow-up in Medullary Thyroid Carcinoma..Medullary Thyroid Carcinoma.2015;ChamSpringer International Publishing207-25

[4] Nervo A,Retta F.Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues..J Endocrinol Invest2021;44:403-19 PMCID:PMC7878269

[5] Phay JE.Metastatic mechanisms in follicular cell-derived thyroid cancer..Endocr Relat Cancer2013;20:R307-19 PMCID:PMC4196318

[6] Pacini F,Luster M,Robinson B.Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions..Expert Rev Endocrinol Metab2012;7:541-54

[7] Marcus C,Surasi DS,Subramaniam RM.PET/CT in the management of thyroid cancers..AJR Am J Roentgenol2014;202:1316-29

[8] Nanni C,Fanti S.Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer..Biomed Pharmacother2006;60:409-13

[9] Treglia G,Muoio B,Ceriani L.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview..Int J Endocrinol2013;2013:856189 PMCID:PMC3638656

[10] Dong MJ,Zhao K.Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis..Nucl Med Commun2009;30:639-50

[11] Kim SJ,Pak K.Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab..Endocr Relat Cancer2018;25:643-52

[12] Qichang W,Gege Z.Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis..Eur J Endocrinol2019;181:93-102

[13] Lee DY.Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis..Clin Nucl Med2020;45:604-10

[14] Moher D,Tetzlaff J.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement..PLoS Med2009;6:e1000097 PMCID:PMC2707599

[15] Campbell I.Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations..Stat Med2007;26:3661-75

[16] Whiting PF,Westwood ME.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies..Ann Intern Med2011;155:529-36

[17] Wallace BC,Trikalinos TA,Trow P.Closing the Gap between Methodologists and End-Users: R as a Computational Back-End..J Stat Soft2012;49:

[18] Zamora J,Muriel A,Coomarasamy A.Meta-DiSc: a software for meta-analysis of test accuracy data..BMC Med Res Methodol2006;6:31 PMCID:PMC1552081

[19] Freudenberg LS,Kühl H.Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer..Eur Radiol2007;17:3139-47

[20] Klain M,Nicolai E.Comparison of simultaneous ¹⁸F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer..Eur J Nucl Med Mol Imaging2020;47:3066-73

[21] Kundu P,Sharma P,Malhotra A.Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT..Eur J Nucl Med Mol Imaging2014;41:1354-62

[22] Leboulleux S,Borget I.Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels..Thyroid2012;22:832-8

[23] Nagamachi S,Kiyohara S.Comparison of diagnostic and prognostic capabilities of ¹⁸F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer..Jpn J Radiol2011;29:413-22

[24] Nakajo M,Jinguji M.Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies..Radiology2013;267:891-901

[25] Ota N,Iwano S.Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study..Br J Radiol2014;87:20130444 PMCID:PMC4064540

[26] Piccardo A,Morbelli S,Barbera F,Altrinetti V,Cabria M.Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?.Q J Nucl Med Mol Imaging2011;55:57-65

[27] Piccardo A,Puntoni M.Role of ¹⁸F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients..Thyroid2019;29:549-56

[28] Poisson T,Leboulleux S.18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer..Eur J Nucl Med Mol Imaging2010;37:2277-85

[29] Qiu ZL,Song HJ.Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer..Nucl Med Commun2012;33:1232-42

[30] Sakurai Y,Iwano S,Ogawa H.Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer..J Med Imaging Radiat Oncol2013;57:297-305

[31] Shinto AS,Mallia M.Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels..World J Nucl Med2015;14:101-8 PMCID:PMC4455165

[32] IntHout J,Borm GF.Small studies are more heterogeneous than large ones: a meta-meta-analysis..J Clin Epidemiol2015;68:860-9

[33] Vrachimis A,Wenning C.[(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer..Eur J Nucl Med Mol Imaging2016;43:212-20

[34] Vrachimis A,Wenning C.[(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer..Eur J Nucl Med Mol Imaging2016;43:1765-72